JP2022116251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022116251A5 JP2022116251A5 JP2022089010A JP2022089010A JP2022116251A5 JP 2022116251 A5 JP2022116251 A5 JP 2022116251A5 JP 2022089010 A JP2022089010 A JP 2022089010A JP 2022089010 A JP2022089010 A JP 2022089010A JP 2022116251 A5 JP2022116251 A5 JP 2022116251A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pharmaceutical dosage
- root extract
- valerian root
- acidifying agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 30
- 239000002535 acidifier Substances 0.000 claims description 25
- 239000011159 matrix material Substances 0.000 claims description 15
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 6
- 244000126014 Valeriana officinalis Species 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 235000016788 valerian Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 229940038779 valerian root extract Drugs 0.000 claims 28
- 239000001192 valeriana officinalis l. rhizome/root Substances 0.000 claims 28
- 238000009472 formulation Methods 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- 238000013268 sustained release Methods 0.000 claims 8
- 239000012730 sustained-release form Substances 0.000 claims 8
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 4
- 229920001661 Chitosan Polymers 0.000 claims 4
- 229920002307 Dextran Polymers 0.000 claims 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229940072056 alginate Drugs 0.000 claims 4
- 235000010443 alginic acid Nutrition 0.000 claims 4
- 229920000615 alginic acid Polymers 0.000 claims 4
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 4
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 4
- 229940014041 hyaluronate Drugs 0.000 claims 4
- 239000000017 hydrogel Substances 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920000609 methyl cellulose Polymers 0.000 claims 4
- 239000001923 methylcellulose Substances 0.000 claims 4
- 235000010981 methylcellulose Nutrition 0.000 claims 4
- 239000001814 pectin Substances 0.000 claims 4
- 229920001277 pectin Polymers 0.000 claims 4
- 235000010987 pectin Nutrition 0.000 claims 4
- 229960000292 pectin Drugs 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- 229920001987 poloxamine Polymers 0.000 claims 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000004626 polylactic acid Substances 0.000 claims 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims 4
- 239000011118 polyvinyl acetate Substances 0.000 claims 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 239000011975 tartaric acid Substances 0.000 claims 4
- 235000002906 tartaric acid Nutrition 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 1
- 229960003987 melatonin Drugs 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 229940095602 acidifiers Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 1
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332728P | 2016-05-06 | 2016-05-06 | |
| US62/332,728 | 2016-05-06 | ||
| PCT/US2017/031046 WO2017192843A1 (en) | 2016-05-06 | 2017-05-04 | Valerian composition and related methods |
| JP2018558279A JP7576905B2 (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558279A Division JP7576905B2 (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022116251A JP2022116251A (ja) | 2022-08-09 |
| JP2022116251A5 true JP2022116251A5 (enExample) | 2024-06-24 |
| JP7577090B2 JP7577090B2 (ja) | 2024-11-01 |
Family
ID=60203773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558279A Active JP7576905B2 (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
| JP2022089010A Active JP7577090B2 (ja) | 2016-05-06 | 2022-05-31 | バレリアン組成物及び関連方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558279A Active JP7576905B2 (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10342873B2 (enExample) |
| EP (1) | EP3452020A4 (enExample) |
| JP (2) | JP7576905B2 (enExample) |
| KR (1) | KR20190008265A (enExample) |
| CN (2) | CN109310638A (enExample) |
| AU (1) | AU2017260019A1 (enExample) |
| CA (1) | CA3023305C (enExample) |
| MX (1) | MX2018013569A (enExample) |
| RU (1) | RU2018142019A (enExample) |
| WO (1) | WO2017192843A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11723862B2 (en) * | 2020-01-17 | 2023-08-15 | Societe Des Produits Nestle S.A. | Dosage form with sustained release melatonin pellets |
| IT202200013576A1 (it) * | 2022-06-27 | 2023-12-27 | S I I T S R L Servizio Int Imballaggi Termosaldanti | Compressa multistrato a rilascio differenziato di melatonina e principi attivi |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2699075A1 (fr) * | 1992-12-11 | 1994-06-17 | Rech Sarl Ab | Préparation médicinale à libération programmable dans le temps notamment à base de plantes. |
| FR2713636B1 (fr) | 1993-12-07 | 1996-01-05 | Adir | Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2727315A1 (fr) | 1994-11-30 | 1996-05-31 | Cooperative Agricole Laitiere | Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| WO1998025606A1 (en) | 1996-12-10 | 1998-06-18 | Bristol-Myers Squibb Company | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
| JP2003505426A (ja) | 1999-07-21 | 2003-02-12 | アンシル ファーマシューティカルズ，インコーポレイテッド | バレリアン根の抽出方法 |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US20050220869A1 (en) * | 2001-12-20 | 2005-10-06 | Federico Stroppolo | Particulate compositions |
| WO2005097101A1 (ja) * | 2004-04-06 | 2005-10-20 | Taiyokagaku Co., Ltd. | 睡眠改善用組成物 |
| JP5154924B2 (ja) | 2004-05-11 | 2013-02-27 | エガレット エイ／エス | ジェランガムを含む膨張可能な投与形態 |
| EP1824450B1 (en) | 2004-10-11 | 2012-11-14 | Nasaleze Patents Limited | Compositions for intranasal administration |
| AU2006260201B2 (en) | 2005-06-22 | 2011-10-20 | Takeda Pharmaceutical Company Limited | Tablet containing hardly soluble active ingredient |
| CA2642761A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| CN1850212A (zh) * | 2006-02-28 | 2006-10-25 | 潮州市强基制药厂 | 一种缬草油液体硬胶囊及其制备方法 |
| WO2008037707A2 (de) | 2006-09-27 | 2008-04-03 | Finzelberg Gmbh & Co. Kg | Baldrian-extraktzubereitung |
| US20080248106A1 (en) | 2007-04-05 | 2008-10-09 | Marvin Heuer | Melatonin-based composition for improved sleep |
| US20090197974A1 (en) * | 2008-02-05 | 2009-08-06 | Khaleeq Ahmed | Natural dietary supplement tablet |
| WO2010084182A1 (en) | 2009-01-23 | 2010-07-29 | Universität Wien | Methods for making valerenic acid derivatives and their use |
| US20110064720A1 (en) | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
| CN102370833B (zh) * | 2010-08-17 | 2014-03-26 | 北京亚东生物制药有限公司 | 一种解表祛暑的泡腾剂及其制备方法和用途 |
| CN102058630B (zh) * | 2010-12-16 | 2014-03-19 | 苏州大学 | 一种镇静安神的缬草制剂及其制备方法 |
| CN102247443A (zh) * | 2010-12-23 | 2011-11-23 | 祝凤仪 | 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法 |
| CN103429223A (zh) | 2011-01-17 | 2013-12-04 | 武田药品工业株式会社 | 口腔分散片 |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| CN102114060B (zh) * | 2011-02-22 | 2012-12-12 | 都晓伟 | 黑水缬草提取物及其制备方法和应用 |
| JP2013053144A (ja) * | 2011-08-09 | 2013-03-21 | Daiichi Sankyo Healthcare Co Ltd | 鎮静剤組成物 |
| US20130116215A1 (en) * | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| EP2806756B1 (en) | 2012-01-26 | 2021-10-27 | Incredible Foods, Inc. | Enclosing materials in natural transport systems |
| EP4502609A3 (en) | 2012-01-26 | 2025-04-09 | Vanda Pharmaceuticals Inc. | Determining a circadian rhythm |
| WO2014083438A2 (en) | 2012-11-09 | 2014-06-05 | Abattis Bioceuticals Corp | Nitric oxide increasing nutritional supplements and methods |
| US20140271890A1 (en) | 2013-03-14 | 2014-09-18 | Thaer Ahmad | Controlled-release pharmaceutical composition |
| HUE042996T2 (hu) | 2013-04-23 | 2019-07-29 | Zx Pharma Llc | Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény |
| PL231923B1 (pl) | 2013-10-28 | 2019-04-30 | Proteon Pharmaceuticals Spolka Akcyjna | Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania |
| RU2535020C1 (ru) | 2014-01-23 | 2014-12-10 | Карпов Алексей Николаевич | Фармацевтическая композиция седативного и спазмолитического действия |
| EP3632416A1 (en) * | 2014-02-06 | 2020-04-08 | Lan Bo Chen | Composition and method for aiding sleep |
| CA2948070C (en) * | 2014-05-05 | 2024-02-13 | Boehringer Ingelheim International Gmbh | Fast dissolving granulate |
| HUE031669T2 (en) | 2014-07-14 | 2017-07-28 | Dr Willmar Schwabe Gmbh & Co Kg | Cataract extract and lavender oil combination for sleeping disorders |
-
2017
- 2017-05-04 KR KR1020187035039A patent/KR20190008265A/ko not_active Ceased
- 2017-05-04 MX MX2018013569A patent/MX2018013569A/es unknown
- 2017-05-04 CN CN201780027996.7A patent/CN109310638A/zh active Pending
- 2017-05-04 CA CA3023305A patent/CA3023305C/en active Active
- 2017-05-04 AU AU2017260019A patent/AU2017260019A1/en not_active Abandoned
- 2017-05-04 WO PCT/US2017/031046 patent/WO2017192843A1/en not_active Ceased
- 2017-05-04 RU RU2018142019A patent/RU2018142019A/ru not_active Application Discontinuation
- 2017-05-04 CN CN202311459688.5A patent/CN117482062A/zh active Pending
- 2017-05-04 US US15/586,709 patent/US10342873B2/en active Active
- 2017-05-04 EP EP17793336.3A patent/EP3452020A4/en active Pending
- 2017-05-04 JP JP2018558279A patent/JP7576905B2/ja active Active
-
2019
- 2019-07-03 US US16/502,976 patent/US11141484B2/en active Active
- 2019-07-09 US US16/506,443 patent/US11141485B2/en active Active
-
2021
- 2021-09-08 US US17/469,458 patent/US11701425B2/en active Active
-
2022
- 2022-05-31 JP JP2022089010A patent/JP7577090B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102726728B1 (ko) | 과다 졸림증을 치료하기 위한 방법 및 조성물 | |
| ES2330873T3 (es) | Composicion para dosificacion oral de liberacion prolongada. | |
| JP5816091B2 (ja) | ナトリウムオキシベートの即時放出投薬形態 | |
| US20250120919A1 (en) | Compositions of midodrine and methods of using the same | |
| KR20100129776A (ko) | 왁스를 포함하는 서방형 제형 | |
| KR102663478B1 (ko) | 에다라본 약제학적 조성물 | |
| JP2010511663A5 (enExample) | ||
| JP2018517715A5 (enExample) | ||
| WO2022183029A1 (en) | Methods and compositions for treating agitation | |
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| JP2022116251A5 (enExample) | ||
| CN118267385A (zh) | 一种布瓦西坦药物组合物、其制备方法及应用 | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| AU2021204247A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| JPWO2007123021A1 (ja) | 徐放性錠剤の製造方法 | |
| JP2019514977A5 (enExample) | ||
| US20040029843A1 (en) | Rapidly disintegrating formulations for treating or preventing mucositis | |
| TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
| JP6995463B2 (ja) | 末梢血管疾患を有する患者における間欠跛行の症状を軽減するために用いられるキノリノン誘導体シロスタゾールの新規製剤 | |
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 | |
| JP2010516712A5 (enExample) | ||
| US10765668B2 (en) | Oral tablet composition comprising dexlansoprazole, oral tablet comprising the same and method for manufacturing the same | |
| CN105163723A (zh) | 具有特定体外溶解曲线或药动学参数的多奈哌齐的药物组合物 | |
| CN101596158A (zh) | 一种对乙酰氨基酚、伪麻黄碱和右美沙芬的复方缓释制剂 | |
| AU2014222375A1 (en) | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |